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active rejection. Type I is tubulointerstitial rejection without The Banff 97 working classification of renal allograft pathology.
arteritis. Type II is vascular rejection with intimal arteritis, and Background. Standardization of renal allograft biopsy intertype III is severe rejection with transmural arterial changes. pretation is necessary to guide therapy and to establish an Biopsies with only mild inflammation are graded as "borobjective end point for clinical trials. This manuscript describes derline/suspicious for rejection." Chronic/sclerosing allograft a classification, Banff 97, developed by investigators using the changes are graded based on severity of tubular atrophy and Banff Schema and the Collaborative Clinical Trials in Transinterstitial fibrosis. Antibody-mediated rejection, hyperacute plantation (CCTT) modification for diagnosis of renal allograft or accelerated acute in presentation, is also categorized, as are pathology.
other significant allograft findings. Methods. Banff 97 grew from an international consensus discussion begun at Banff and continued via the Internet. This
Conclusions. The Banff 97 working classification refines earschema developed from (a) analysis of data using the Banff lier schemas and represents input from two classifications most classification, (b) publication of and experience with the CCTT widely used in clinical rejection trials and in clinical practice modification, (c) international conferences, and (d) data from worldwide. Major changes include the following: rejection with recent studies on impact of vasculitis on transplant outcome.
vasculitis is separated from tubulointerstitial rejection; severe Results. Semiquantitative lesion scoring continues to focus rejection requires transmural changes in arteries; "borderline" on tubulitis and arteritis but includes a minimum threshold for rejection can only be interpreted in a clinical context; antibodyinterstitial inflammation. Banff 97 defines "types" of acute/ mediated rejection is further defined, and lesion scoring focuses on most severely involved structures. Criteria for specimen adequacy have also been modified. Banff 97 represents a significant refinement of allograft assessment, developed via inter-Standardization of renal allograft biopsy interpretation and reporting is necessary to guide therapy in trans- held in Banff, Canada on August 2 to 4, 1991, was pub-3. Borderline changes: "Suspicious" for acute rejection lished in 1993 [1] , has been clinically validated in numerThis category is used when no intimal arteritis is present, but there ous studies [2] [3] [4] [5] [6] [7] [8] , and is now widely used by center Banff 97, the combined classification described here,
is a product of an international consensus discussion ified schema for renal allograft rejection was brought 6. Other Changes not considered to be due to rejection, see Table 14 .
about through several major influences, including (a)
a The recommended format of report is a descriptive narrative signout followed analysis of data from clinical trials using the Banff classiby numerical codes in parentheses. Categorization should in the first instance fication and observation of actual practice in use of the be based solely on pathologic changes, then integrated with clinical data as a second step. More than one diagnostic category may be used if appropriate.
classification worldwide, (b) publication of and experib Glomerular and vascular lesions help define type of chronic nephropathy; ence in the use of the CCTT modification [9] , and (c) chronic/recurrent rejection can be diagnosed if typical vascular lesions are seen.
international consensus discussions that took place at the Second, Third [10] , and Fourth Banff Conferences and at intervening meetings. In addition, data on prognoBanff 93-95. Nonetheless, the new version retains the sis and renal function from the Syntex/Roche mycophebasic construct of the earlier schema, which includes nolate mofetil trials [11] , data from the CCTT trials [9] , the range of findings seen in allograft biopsies and also and a recent study focused on vascular lesions in rejecprovides for semiquantitative grading of changes of both tion [12] have demonstrated that vasculitis of any severacute/active rejection and chronic/sclerosing allograft neity has significant implications for response to therapy, phropathy. To clarify the changes made, the categorizaand graft function and outcome, and provide a major tion and grading of acute changes are discussed in the rationale for this 1997 revision ("Banff 97"). This comcontext of the earlier schemas, Banff 93-95 and CCTT. bined classification focuses on histologic "types" rather
The initial modification of the schema is a change than "grades" of rejection. Since there are significant in definition of specimen adequacy. To diagnose and changes in this revised schema, there is strong incentive categorize rejection, adequate cortex must be present in in many circumstances to retain the older classifications, the material examined, and the change has been made but to incorporate Banff 97 when a new study is initiated.
to ensure more adequate cortical sampling. With the new emphasis on arteritis, a more generous minimal RESULTS arterial sampling is also recommended. For Banff 97, an Banff 97, presented in Table 1 , represents a significant "adequate" specimen is now defined as a biopsy with 10 or more glomeruli and at least two arteries; the threshold modification of the grading of acute/active rejection in for a minimal sample is seven glomeruli and one artery. It is also recommended that at least two separate cores containing cortex be obtained or that there be two sepabe sought in the most inflamed areas in the biopsy. Inrate areas of cortex in the same core. The recommendaflammatory tubular injury and/or breakdown of tubular tion for slide preparation is seven slides containing multibasement membranes are included as significant histople sequential sections, three stained with hematoxylin logic findings in Banff 93-95 and the CCTT modification, and eosin (HE) stain, three with periodic acid-Schiff and are included in Banff 97 in the "t3" grade. Since (PAS) stain or silver stains, and one with a trichrome tubulitis is seen routinely in atrophic tubules in native stain. The PAS stain and silver stains enhance the identikidneys and cannot be interpreted as a specific response fication of glomerulitis and tubulitis and any destruction to alloantigen, tubulitis should not be graded in moderof tubular basement membranes. These stains also enately-to-severely atrophic tubules, that is, tubules rehance the recognition of chronic features such as arterioduced in caliber by 50% or more. lar hyaline, increased mesangial matrix, double contours Arteritis is likewise a defining feature for rejection in glomerular capillaries, and thickened tubular basediagnosis in the allograft. Both Banff 93-95 and the ment membranes. The trichrome stain is useful in defin-CCTT formulations distinguish intimal arteritis, careing interstitial fibrosis. It is recommended that histologic fully defined as lymphocytic infiltration beneath the ensections should be cut at 3 to 4 microns, as the current dothelium, from arteritis with inflammation in the media definitions of lesion grading are not appropriate either and/or with fibrinoid necrosis of the vessel wall. Parenfor 1 micron plastic sections or for "routine" thicker chymal necrosis and/or interstitial hemorrhage were recsections obtained at some institutions.
ognized as possible manifestations of severe arteritis by both classifications. Banff 93-95 vasculitis ("v") scores Acute/active lesion scoring focused on intimal arteritis, with v1 defined as mild-toSemiquantitative lesion scoring provides the morphomoderate in at least one artery, v2 as moderate-to-severe logic basis for the rejection classification. While the basic in more than one artery, and v3 as severe in many arterial cross-sections and/or with transmural arteritis, fibrinoid features used to diagnose rejection are tubulitis and arteritis, a minimal threshold for interstitial inflammation change, and necrosis. However, because there is the potential for significant sampling error in defining vasculitis, must be reached to diagnose rejection of the tubulointerstitial type. Glomerulitis, although not a specific criterion it was agreed that the focus of grading should be on the most severely involved vessel (analogous to tubulitis for rejection, may have implications for late graft function, and is also graded. Tubulitis and vasculitis, as the scoring). A score of v3, or severe vasculitis (v3), is now reserved for those cases with transmural arteritis and/or cardinal features of rejection, will be considered first.
The Banff 93-95 schema grades tubulitis ("t" score) arterial fibrinoid change and smooth muscle necrosis with accompanying lymphocytic inflammation in the vesbased on the greatest number of infiltrating mononuclear cells in the tubular epithelium (that is, having breached sel (Table 3) . In reporting vasculitis, the total number of arteries and the total number involved by vasculitis the tubular basement membrane and lying beneath or between tubular cells) per tubular cross section; if the should be recorded. If there is interstitial hemorrhage and/or infarction, an asterisk should be added to the "v" tubule is sectioned longitudinally, results are expressed per 10 tubular cells (the average number of cells per score. Interstitial hemorrhage and/or infarction alone (that is, v0*), while raising the specter of rejection with cross-section). In the CCTT modification, significant tubulitis is defined by number of tubules with tubulitis in vascular involvement not sampled by the biopsy, is no longer considered adequate to presumptively score v3. 10 serial high-powered fields from the area with the most inflammatory infiltrate. Banff 97 retains a focus on most
While not itself a signal criterion for rejection, a background of interstitial inflammation is required to diagseverely inflamed tubules to grade tubulitis and requires that the tubulitis be present in more than one focus in nose rejection of the tubulointerstitial type. Because minimal (and even significant) mononuclear inflammathe biopsy ( Table 2) . The most inflamed tubules should Acute/active rejection in the Banff 93-95 schema was divided into three grades: I, mild, characterized by moderate tubulitis; II, moderate, further divided into IIa with marked tubulitis and no vasculitis and IIb with mild-totion is present in many protocol biopsies from asymptommoderate intimal arteritis; and III, severe, characterized atic patients, at least 10% of cortex must be inflamed by severe intimal arteritis or transmural arteritis or intraas a threshold for grading of interstitial inflammation. mural necrosis. In this earlier Banff classification, recent Severe inflammation (i3) is defined when greater than focal infarction and interstitial hemorrhage without obvi-50% of the cortex is inflamed ( Table 4 ). Areas that ous cause could be regarded as grade III rejection. In cannot be meaningfully graded for assessment of interstithe CCTT modification, acute/active rejection was ditial infiltrates are fibrotic areas, the immediate subcapsuvided into three types: I, with significant tubulitis; II, lar cortex, and the adventitia around large veins and with arterial or arteriolar endothelialitis; and III, with lymphatics. The infiltrate in classic cellular rejection conarterial fibrinoid necrosis or transmural inflammation. sists of T lymphocytes and monocyte/macrophages. If
The Banff 97 classification of acute/active rejectionrelated changes is shown in Table 6 , and is compared with there are more than 5 to 10% eosinophils, neutrophils, rejection categories from Banff 93-95 and the CCTT or plasma cells in the infiltrate, an asterisk is added to modification. In view of the recent studies that provide the "i" score, and other differential diagnoses should evidence that vasculitis per se has implications for rebe considered, for example, hypersensitivity reaction or sponse to therapy and/or graft survival [9, 11, 12] , Banff infection, as discussed later here. Moreover, the quality 97 focuses on types of rejection. Type I is tubulointerstiof the infiltrate must be analyzed in the context of clinical tial rejection without arteritis, further divided into type information. For example, tapering and withdrawal of IA with focal moderate tubulitis and IB with severe immunosuppression may be followed by rejection infiltubulitis. Type II, vascular rejection, is characterized by trates with a substantial component of plasma cells.
intimal arteritis, further divided into IIA if the intimal Glomerulitis is graded in both the CCTT and Banff arteritis is mild-to-moderate, and IIB if severe. Type classifications, although it is not used as a criterion for III, severe rejection, is with transmural arteritis with or rejection since its significance has been and remains conwithout fibrinoid and smooth muscle necrosis. Those troversial. The Banff schema grades glomerulitis, defined cases with only mild tubulitis and/or with only mild focal by mononuclear cell infiltrate and endothelial cell eninterstitial inflammation remain in a "borderline" catelargement, by the percentage of glomeruli involved and gory. whether the process is segmental or global within inAs in the previous working classifications, antibodyvolved glomeruli. In the CCTT, glomerulitis may be abmediated rejection is also included, but now recognizing sent, "focal," or "severe." The grading of glomerulitis in two forms, immediate (hyperacute) and delayed (accelBanff 97 is shown in Table 5 , with g1 defined as glomeruerated acute). Except in classic hyperacute rejection oclitis in less than 25% of glomeruli and g3 as glomerulitis curring immediately post-transplant, antibody-mediated that is mostly global and in more than 75% of glomeruli. rejection should be confirmed by repeat cross-match, as Polymorphonuclear leukocytes in glomerular capillaries discussed below. Antibody-mediated rejection can occur are not a feature of transplant glomerulitis, but may be as an isolated rejection response or combined with cellseen in antibody-mediated rejection or in early thrommediated rejection as an antibody-mediated component. The morphology of classic "pure" antibody-mediated botic microangiopathy. Table 7 . Quantitative criteria for interstitial fibrosis ("ci") Table 9 . Quantitative criteria for allograft glomerulopathy ("cg") ci0 -Interstitial fibrosis in up to 5% of cortical area cg0 -No glomerulopathy -double contours in Ͻ10% of peripheral capillary loops in most severely affected glomerulus ci1 -Mild -interstitial fibrosis in 6 to 25% of cortical area ci2 -Moderate -interstitial fibrosis in 26 to 50% of cortical area cg1 -Double contours affecting up to 25% of peripheral capillary loops in the most affected of nonsclerotic glomeruli ci3 -Severe -interstitial fibrosis in Ͼ50% of cortical area cg2 -Double contours affecting 26 to 50% of peripheral capillary loops in the most affected of nonsclerotic glomeruli cg3 -Double contours affecting more than 50% of peripheral capillary loops in the most affected of nonsclerotic glomeruli Table 8 with renal ischemia, hypertension, drug effects, infection, increased ureteral pressure, and nonimmune inflammatory processes, in addition to a subset due to chronic or recurring immune reaction to the graft [13] . Chronic increase ("mm" score) is shown in Table 10 . Transplant glomerulopathy often also includes mesangiolysis and changes may be seen in glomeruli, interstitium, tubules, and vessels, although not necessarily simultaneously or progressive sclerosing changes; the latter may be difficult to distinguish from membranoproliferative glomeruloto the same degree. Because sampling error is less of a problem in sampling of tubules and interstitium, these nephritis or, in some cases, focal segmental glomerulosclerosis. features are the basis of the grading of severity of chronic allograft nephropathy. The grading of chronic interstitial Vascular changes potentially enable identification of kidneys with chronic/sclerosing changes due to chronic fibrosis and tubular atrophy and/or loss remains unchanged from Banff 93-95, with quantitation based on rejection. Specific chronic vascular changes that suggest that vascular changes are due to "chronic rejection" are the percentage of cortical parenchyma involved (Tables  7 and 8). disruptions of the elastica, best seen on special stains, and inflammatory cells in the fibrotic intima. Proliferation of The grading of chronic glomerular changes related to rejection, previously defined by mesangial matrix inmyofibroblasts in the expanded intima and formation of a second "neointima" are also useful features [15, 16] . crease and basement membrane thickening, has now been refined. The presence of "double contours" in capFibrointimal thickening in vessels without these features is a significant finding, especially if it is of new onset and illary loops, created by mesangial interposition, is the most specific change of chronic transplant glomerulopais graded, but it is not regarded as specific for "chronic rejection." Recognizing that vascular changes may be thy [14] , whereas mesangial matrix increase is a potentially important but less specific finding. Therefore, the focal, chronic vascular changes are graded based on the extent of occlusion of the most severely affected vessel two are now graded separately. Severity of chronic glomerulopathy is now graded by the extent of "double con- (Table 11) . Finally, arteriolar hyaline change, particularly if nodutours" in the most severely affected glomerulus. The total number of glomeruli and the total number of nonlar and documented to be of new onset, may be an important manifestation of cyclosporine or FK506 toxicity [17] , specifically sclerotic glomeruli must be recorded (Table  9 ). An increase in mesangial matrix is graded by the as discussed later here, and has a separate lesion scoring in the schema. The scoring of this lesion remains unpercentage of nonsclerotic glomeruli with at least moderate mesangial matrix increase. Moderate mesangial machanged from Banff 93-95 (Table 12) . Arteriolitis is a lesion that is currently of uncertain significance; if prestrix increase, in turn, is defined by expansion of the matrix in the mesangial interspace between adjacent gloent, it is designated by an asterisk added to the "arteriolar hyalinosis" ("ah") score. merular capillaries to exceed the width of two mesangial cells in at least two lobules. Grading of mesangial matrix Because it is often impossible to define the precise fication follows earlier classifications that took the apcause or causes of chronic allograft damage, the term proach of semiquantitative grading of rejection lesions "chronic/sclerosing allograft nephropathy" is preferable to provide an acute rejection index. Finkelstein et al to "chronic rejection," which implies allogeneic mechapublished such a classification in 1976, in the pre-cyclonisms of injury, unless there are specific features to insporine era [19] . This classification graded interstitial criminate such a rejection process. However, recognition inflammation, glomerulitis, and arteritis; intimal arteritis of those cases that do represent "chronic/recurrent rejecand tubulitis were not recognized separately. Mild rejection" may be important, as there are preliminary data tion had interstitial inflammation; moderate and severe suggesting that therapy may be efficacious in these cases rejection were characterized by vasculitis. Banfi et al [18] . In chronic/sclerosing allograft nephropathy, grades published a similar classification in the same era [20], 1 (mild), 2 (moderate), and 3 (severe), as mentioned recognizing an irreversible form of rejection with large earlier here, may be modified by "a" (no changes strongly artery changes and infarction. In 1983, Matas et al prosuggestive of chronic rejection in glomeruli and/or vesposed a schema with eight grades, the first four defined sels present) or "b" (changes strongly suggestive of by minimal-to-severe tubulointerstitial nephritis, categochronic rejection present (Table 1) . If convincing diagries 5 through 7 defined by minimal-to-moderate vasculinostic features are present, a diagnosis of "chronic/recurtis, and category 8 reserved for cases with severe vascular rent rejection" can be made.
rejection with fibrinoid necrosis [21] . These grades showed a general correlation with survival, although The Banff 97 combined working classification numbers in some of the categories were too small to The Banff 97 combined classification of renal allograft draw firm conclusions. pathology includes acute/active rejection, chronic/scleSeveral studies have concluded that the presence of rosing allograft nephropathy, and other morphologic vasculitis in a renal allograft biopsy is associated with findings, including de novo and recurrent diseases, toxic poorer response to therapy and/or outcome. For examchanges, and infection (Tables 1 and 13 ). Major changes ple, Visscher et al found that in cases with steroid-resisfrom the previous Banff schema are summarized in tant rejection, the response to OKT3 was lower in those in biopsies from well-functioning allografts as well and is, therefore, not included as a criterion for rejection.
Rush et al established a protocol in which they biopsied asymptomatic patients at intervals post-transplant summarized briefly later here, reach a conclusion similar to these earlier studies, and have led to the Banff 97 [26] . Using Banff criteria, they found that approximately one-third of these patients had "subclinical rejection," categorization of acute/active rejection changes as "types" (tubulointerstitial or vascular) rather than "grades" of that is, i2t2 with a less than 10% change in serum creatinine. Patients randomized to early protocol biopsies and rejection.
The Roche mycophenolate mofetil study [11] included treatment of this "subclinical rejection" had a significantly lower creatinine at 24 months than those patients 87 biopsies scored blinded to clinical history or outcome using the Banff criteria. The highest tubulitis and vasculirandomized to the control arm [27] . This finding suggests that the threshold of i2t2 for the diagnosis of rejection tis scores in the biopsy/biopsies obtained post-transplant from each case, as defined by the Banff 93-95 grading is likely appropriate, even in those cases with no change in serum creatinine, since untreated chronic graft injury system, were recorded. The finding of vasculitis of any grade was significantly correlated with allograft loss. may result. The significance of "borderline" rejection [mild tubulOutcome, defined by graft survival, was independent of rejection therapy cohort.
itis (t1) only, or focal tubulitis with only mild interstitial inflammation (i1)] has been difficult to define. If mild In a study of the modified Banff grading system used in the CCTT [9] , in which type I rejection is defined by tubulitis, as defined by the Banff criteria, was included as a criterion for rejection in the study by Rush et al, tubulointerstitial inflammation, type II by intimal arteritis, and type III by arterial necrosis or transmural inover 50% of the patients would have subclinical rejection, likely leading to unnecessary increase in immunoflammation, there was a significant correlation of these patterns with severity of clinical rejection. Clinically sesuppressive therapy. A few studies have looked at this "borderline" cohort. In some series, patients with borvere rejection was defined in these protocols as a rejection episode that was steroid resistant, treated with ATG, derline rejection usually responded to antirejection therapy; however, the finding of borderline changes with OKT3, or FK506, or was of early onset, occurring within 10 days of transplantation. The odds ratio for severe mild tubulitis does not always correlate with clinical rejection as defined by response to therapy [28] [29] [30] . In rejection was 6.2 for Type I and 37.9 for Type II. Since this classification does not provide semiquantitative some centers, biopsies are obtained after treatment is initiated so that inflammatory changes may have dimingrading of severity of individual inflammatory changes, no correlations with severity of inflammatory changes ished in individuals that did indeed have a significant rejection episode; in this circumstance, i1t2 lesions may, were defined, except that extent of tubulitis or interstitial infiltrate did not correlate with severity.
in fact, have clinical significance as an indicator of rejection. It is clear that these mild inflammatory changes In a more recent study, Nickeleit et al analyzed the prognostic significance of vascular lesions in rejection can only be adequately interpreted in a clinical context; borderline changes in biopsies obtained in the context [12] . They found that rejection with endarteritis was sig-of decreased function may require therapy, whereas bormajor grading system that focuses on chronic changes is the Chronic Allograft Damage Index (CADI), which derline changes in protocol biopsies performed on patients with stable graft function may not [30] . Possible provides semiquantitative assessment of a number of chronic and inflammatory features that have been validiagnoses for this category include the following: suspicious for acute rejection, borderline for acute rejection, dated as clinically relevant predictors of allograft outcome [35] . The CADI and the Banff schema have been borderline inflammatory changes only, possible (early) acute rejection, probable (early) acute rejection. The adjusted to provide equivalent information. It must be emphasized that although rejection-related final designation may depend on center experience, therapy, time after transplant, and other clinical and morphochanges are a focus of the Banff 97 schema, there are a number of other disease processes that may involve the logical features, including other signs of inflammatory cell activation or tissue injury.
allograft and must be considered in the differential diagnosis (Table 13 ). Those processes that produce inflamThe criteria for rejection diagnosis in the CCTT modification included tubulitis plus two of the following three matory changes in the allograft must be differentiated from acute rejection. Polymorphonuclear leukocytes criteria: interstitial edema, activated lymphocytes (or blasts), or tubular injury. However, on evaluation of the (PMNL) in the interstitium and especially in tubular lumina may signal acute bacterial infection, although individual pathologic criteria for rejection, removal of these three additional criteria resulted in reclassification they may be seen in cases in which there is significant ischemic injury and infarction (which may in turn be of only two cases, one that responded to antirejection therapy and one that did not [9] . Moreover, in those rejection related). If PMNL are confined to peritubular and glomerular capillaries, the possibility of severe acute centers in which biopsy is frequently performed after steroid bolus therapy, edema and activated lymphocytes endothelial injury and possible antibody-mediated rejection must be considered. While numerous eosinophils are much diminished within one to two days. These additional criteria, however, may occasionally be useful when may be a feature of the inflammatory response to alloantigen, the possibility of a hypersensitivity reaction must combined with other morphologic findings and in clinical context in those cases with borderline changes [31] .
be in the differential as well. Viral infections must always be considered, as inType I and type II rejection are both thought to be manifestations of cell-mediated rejection. However, type flammatory infiltrates in this setting are typically mononuclear, and significant tubulitis may be seen. The speci-II may be seen in and type III is strongly suggestive of an antibody-mediated component to the rejection process. as the appropriate treatment is reduction of immunosuppression for PTLD, but aggressive anti-T-cell therapy relation with outcome in native as well as allograft kidneys [34] , the grading of severity of chronic rejection for severe rejection. Potential differential features have been identified [40] . PTLD typically shows expansile or continues to focus on interstitial fibrosis and tubular atrophy and loss. However, identification of distinctive vascunodular mononuclear infiltrates with irregular foci of serpiginous necrosis. PTLD lesions may be focal or diflar changes may enable the diagnosis of chronic rejection, which in turn may be amenable to therapy [18] . The other fuse, and the latter may result in extensive involvement of the pericalyceal adipose tissue and nerves. The infilolar hyaline eosinophilic deposits comprised of fibrin, IgM, C3, and C1q, which may be difficult to distinguish trates in PTLD generally show the entire spectrum of lymphocyte differentiation, including immunoblasts, from those due to aging, hypertension, and diabetes mellitus. As with CsA, arteriolar myocyte vacuolization can plasma cells, large cleaved/noncleaved cells, and small round lymphocytes. Cells with marked nuclear atypia be seen; this lesion is a nonspecific manifestation of vessel spasm and should be ascribed to tacrolimus toxicity only are usually present and help in the differential diagnosis from rejection. Some biopsies have a monotonous apafter exclusion of other causes of vessel injury. Druginduced vasospasm and the hyalinization of the interlobpearance, and such patients may be histologically and clinically indistinguishable from intermediate-to-high ular arteries and arterioles may lead to ischemic injury accentuated in the medullary rays and probably also the grade lymphomas in nonimmunocompromised patients.
Although they are not as readily found as in severe medullary inner stripe [48], leading to striped or diffuse interstitial fibrosis. rejection, PTLD cells can also be associated with tubulitis. Of course, rejection and PTLD can coexist in a Significant tubulointerstitial inflammation or vasculitis may also be components of recurrent or de novo renal biopsy [41] , making accurate diagnosis especially difficult. In most cases, and especially with limited biopsy disease in the allograft. These differential considerations must be considered at any time post-transplant and bematerial, the final diagnosis must await the results of immunophenotyping, and EBV in situ hybridization.
come more likely as time post-transplant increases. A good pretransplant clinical history can be invaluable in With rare exceptions, PTLD lesions are B-cell preponderant and EBV positive, whereas rejection is associated considering differential diagnoses. Finally, future advances in analysis of renal allograft with a primarily T-cell infiltrate, which is EBV negative. CD20 (B-cell marker) and CD3 (T-cell marker) immubiopsies can already be predicted, and the classification and grading of acute/active rejection will continue to nohistochemistry is a reliable way of phenotyping infiltrates in formalin-fixed material. The most sensitive techevolve. The significance of specific morphologic findings-including glomerulitis, arteriolitis, and infiltrates nique for demonstrating EBV in routinely processed tissue is in situ hybridization for EBV-encoded small with unusual cellular features-for acute and chronic allograft function and outcome will continue to be inves-RNA [42] . In lesions with significant numbers of plasma cells, staining for kappa and lambda light chains is a tigated. Emphasis in biopsy assessment will shift from diagnosis to prediction of later allograft function and convenient way of identifying lesions that are clearly clonal. If sufficient fresh tissue is available, immunogloboutcome, potentially enabling early intervention. Indeed, two recent studies have shown that chronic histoulin gene rearrangement and oncogene studies should also be performed, as molecular findings have also been logic changes detected in early protocol biopsies and graded using the 93-95 Banff schema were predictive related to ultimate prognosis [43] .
Toxic effects of cyclosporine and of tacrolimus also of long-term outcome [49, 50] . Clinical utility of renal allograft biopsies, for both diagnosis and prediction of remain important differential considerations. Toxic effects of cyclosporine have been studied for some time, outcome, will be enhanced by application of immunostaining and molecular studies. Identification of effector but tacrolimus is a relatively new agent, and its toxicity profile is still being defined. Cyclosporine and tacrolimus cells such as NK cells and cytotoxic T-lymphocytes and of monocyte/macrophages may enhance diagnosis and/ share a closely related mechanism of action, which is paralleled by an overlap in the toxicity profile of these or predict later dysfunction. Molecular studies show promise in refining the diagnosis of acute/active rejection two drugs. The pathology of tacrolimus nephrotoxicity appears to be similar to cyclosporine toxicity [44] [45] [46] [47] ,
[51], although much more needs to be done to establish validity in cases with borderline features and to dissemialthough it has been much less completely studied. Tubular vacuolization is the most common finding in biopsies nate the technology. It will be important to establish which molecular markers correlate with interstitial infilperformed during clinical episodes of tacrolimus nephrotoxicity; tubular vacuoles may be seen in proximal as well trates and which correlate with invasive inflammation (tubulitis, intimal arteritis). Also, more precise definition as distal tubules, and although these are often isometric, focal coalescence into larger vacuoles is also present.
of histologic and molecular features of indolent graft injury and sclerosis should enable better understanding As with cyclosporine, tacrolimus therapy may also be associated with microvascular toxicity characterized by of pathogenesis of progressive damage and enable appropriate therapy. There is clearly much work to be done damage to the glomerular capillaries and renal arterioles. Arteriolar damage mediated by tacrolimus sometimes in optimizing the assessment of the renal allograft by the pathologist as we move into the 21st century. Many results in an acute arteriolopathy characterized by endothelial swelling, mucoid intimal thickening, eosinophilic of these issues will receive focused attention at the Fifth Banff Conference on Allograft Pathology in 1999 and in globules in the media, and focal medial necrosis. Scattered thrombi may be seen in capillary loops or afferent other international forums, which have become logical venues for such consensus in the global medical community. arterioles. Prolonged tacrolimus therapy results in arteri- 
